Editorial: Diagnosis and Treatment of Primary Aldosteronism: from Clinical Origin to Translational Research


Primary aldosteronism (PA) is one of the common causes of secondary hypertension, increasing the risk of cardiovascular disease and renal events as compared to essential hypertension, independently of blood pressure control. Primary aldosteronism (PA) is one of the common causes of secondary hypertension, and is associated with higher risks of cardiovascular, renal, and metabolic sequelae, including left ventricular hypertrophy, myocardial infarction, atrial fibrillation, stroke, microalbuminuria, osteoporosis, as well as metabolic syndrome. The present Research Topic highlights the interplay between clinical diagnosis, underlying genetic etiologies, and clinical outcome PA. Overall, it focuses on the histopathologic findings, gene mutation, the coexistence of cortisol, cosecretion, and targeted treatments of PA.

Authors: Wan-Chen Wu, Qiang Wei, Vin-Cent Wu
Keywords: histopathology, gene mutation, cortisol, treatments
DOI Number: 10.3389/fendo.2021.781105      Publication Year: 2021

To search for other research papers by topic, keyword, author, or year, please go to our Publications page.

©2021 Primary Aldosteronism Foundation — All Rights Reserved

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.